Celldex Therapeutics, Inc. — Director's Dealing 2015

Jun 11, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Celldex Therapeutics, Inc. (CLDX)
CIK: 0000744218
Period of Report: 2015-06-10

Reporting Person: LIPTON KAREN SHOOS (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2015-06-10	Common Stock	A	6500	—	Acquired	21833	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2015-06-10	Non-Qualified Stock Option (right to buy)	$25.41	A	10300	Acquired	2025-06-10	Common Stock (10300)	Direct

Footnotes

F1: On June 10, 2015, the Company awarded 6,500 shares of the Company common stock as an annual equity grant in the form of restricted stock awards under the Celldex Therapeutics, Inc. 2008 Stock Option and Incentive Plan, subject to time-based forfeiture restrictions.

F2: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan.

F3: Such option vests in four equal installments beginning September 10, 2015.